Home  »  Business   »  Looking Closely at the Growth Curve for Galera The...

Looking Closely at the Growth Curve for Galera Therapeutics Inc. (GRTX)

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Galera Therapeutics Inc. (NASDAQ:GRTX) went down by -6.03% from its latest closing price compared to the recent 1-year high of $12.99. The company’s stock price has collected -25.27% of loss in the last five trading sessions. Press Release reported on 01/06/22 that Galera to Present at H.C. Wainwright BioConnect Conference

Is It Worth Investing in Galera Therapeutics Inc. (NASDAQ :GRTX) Right Now?

Opinions of the stock are interesting as 3 analysts out of 4 who provided ratings for Galera Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $12.25, which is $12.07 above the current price. GRTX currently public float of 22.97M and currently shorts hold a 2.66% ratio of that float. Today, the average trading volume of GRTX was 12.61M shares.

GRTX’s Market Performance

GRTX stocks went down by -25.27% for the week, with a monthly jump of 139.86% and a quarterly performance of -56.25%, while its annual performance rate touched -67.49%. The volatility ratio for the week stands at 11.88% while the volatility levels for the past 30 days are set at 16.18% for Galera Therapeutics Inc.. The simple moving average for the period of the last 20 days is -4.07% for GRTX stocks with a simple moving average of -48.55% for the last 200 days.

Analysts’ Opinion of GRTX

BofA Securities, on the other hand, stated in their research note that they expect to see GRTX reach a price target of $2, previously predicting the price at $17. The rating they have provided for GRTX stocks is “Underperform” according to the report published on October 19th, 2021.

Credit Suisse gave a rating of “Outperform” to GRTX, setting the target price at $15 in the report published on April 26th of the previous year.

GRTX Trading at 42.08% from the 50-Day Moving Average

After a stumble in the market that brought GRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.60% of loss for the given period.

Volatility was left at 16.18%, however, over the last 30 days, the volatility rate increased by 11.88%, as shares surge +139.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +42.32% upper at present.

During the last 5 trading sessions, GRTX fell by -25.27%, which changed the moving average for the period of 200-days by -66.24% in comparison to the 20-day moving average, which settled at $3.68. In addition, Galera Therapeutics Inc. saw -25.27% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at GRTX starting from West Linda, who purchase 20,000 shares at the price of $2.74 back on Dec 17. After this action, West Linda now owns 60,000 shares of Galera Therapeutics Inc., valued at $54,804 using the latest closing price.

HOLMLUND JON T, the Chief Medical Officer of Galera Therapeutics Inc., sale 47,756 shares at $8.47 during a trade that took place back on Sep 01, which means that HOLMLUND JON T is holding 0 shares at $404,498 based on the most recent closing price.

Stock Fundamentals for GRTX

The total capital return value is set at -76.81, while invested capital returns managed to touch -81.03. Equity return is now at value 458.30, with -90.90 for asset returns.

Based on Galera Therapeutics Inc. (GRTX), the company’s capital structure generated 1,044.51 points at debt to equity in total, while total debt to capital is 91.26. Total debt to assets is 75.99, with long-term debt to equity ratio resting at 1,040.62. Finally, the long-term debt to capital ratio is 90.92.

>> 7 Top Picks for the Post-Pandemic Economy <<

The liquidity ratio also appears to be rather interesting for investors as it stands at 5.58.

Leave a Comment

Your email address will not be published. Required fields are marked *

Is Teradyne Inc. (TER) a Keeper?

Teradyne Inc. (NASDAQ:TER) went up by 3.99% from its latest closing price compared to the recent 1-year high of $168.91. The company’s stock price has

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam